The role and efficacy of Ustekinumab

Ustekinumab (Ustekinumab) is a targeted antibody therapy that suppresses the immune response. It works by reducing the signaling pathways of the pro-inflammatory cytokines IL-12 and IL-23, which play a role in various inflammatory diseases. Studies show that ustekinumab is effective in treating adults and children 6 years and older with moderate to severe plaque psoriasis, in whom other treatments have not worked or cannot be used.

For adults with psoriatic arthritis whose condition has not improved sufficiently with DMARDs, limited treatment is available, and ustekinumab is thought to be beneficial in these patients. In Crohn's disease, ustekinumab's role in reducing symptoms in patients for whom other treatments are refractory or unavailable is considered important, also considering the unmet medical needs of these patients. The side effects of this drug are considered manageable. In ulcerative colitis, studies have shown ustekinumab to be effective in patients for whom other treatments have failed or cannot be used. Side effects of this drug are expected.

The generic drug Ustekinumab has been launched in China and is included in the medical insurance, and is only reimbursed for patients who meet the indications. The price of the 130mg/26ml intravenous injection preparation may be more than 5,000 yuan per box, and the price of the 90mg: 1.0ml*1 subcutaneous injection preparation may be more than 8,000 yuan per box. The price of the 130mg/26ml intravenous injection preparation of Ustekinumab sold overseas may be more than 2,000 US dollars per box, and the price of 45mg: 0.5ml*1 subcutaneous injection preparation per box may be more than 10,000 US dollars. There are currently no generic versions of ustekinumab produced in other overseas countries.